FDA Approves First Drug Meant to Ease Alzheimer’s-Linked Agitation
THURSDAY, May 11, 2023 (HealthDay News) — A medication to treat agitation in Alzheimer’s patients now has approval from the U.S. Food and Drug Administration. The FDA gave supplemental approval to Otsuka Pharmaceutical Company Ltd., and Lundbeck Inc. for Rexulti (brexpiprazole) oral tablets on Thursday. Rexulti is the first FDA-approvedContinue Reading